Metabolomics in Preclinical Drug Safety Assessment: Current Status and Future Trends

Area of Science:

• Systems biology
• Toxicology
• Drug development

Background:

• Metabolomics is a powerful approach for preclinical drug safety assessment.
• It aids in understanding toxicity mechanisms and disease pathogenesis.

Purpose of the Study:

• To review current applications and future trends of metabolomics in toxicology and drug development.
• To highlight metabolomics' role in elucidating adverse outcome pathways and identifying toxicity biomarkers.

Main Methods:

• Review of existing literature on metabolomics applications in toxicology and drug safety.
• Discussion of integration with other 'omics' technologies and computational approaches.

Main Results:

• Metabolomics elucidates biochemical alterations underlying toxicity.
• It improves characterization of environmental exposures and their health impacts.
• Metabolomics is increasingly used in safety evaluations for mechanistic insights.

Conclusions:

• Metabolomics offers significant promise for understanding toxicity, enhancing safety screening, and improving risk assessment.
• Reliability through quality assurance and interlaboratory studies is crucial for regulatory acceptance.
• Future applications will integrate metabolomics with computational, in vitro, and personalized medicine.